JP2008530137A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530137A5
JP2008530137A5 JP2007555369A JP2007555369A JP2008530137A5 JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5 JP 2007555369 A JP2007555369 A JP 2007555369A JP 2007555369 A JP2007555369 A JP 2007555369A JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
skin
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007555369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005327 external-priority patent/WO2006088955A2/en
Publication of JP2008530137A publication Critical patent/JP2008530137A/ja
Publication of JP2008530137A5 publication Critical patent/JP2008530137A5/ja
Pending legal-status Critical Current

Links

JP2007555369A 2005-02-14 2006-02-14 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 Pending JP2008530137A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65311405P 2005-02-14 2005-02-14
US71676205P 2005-09-13 2005-09-13
US74995205P 2005-12-13 2005-12-13
PCT/US2006/005327 WO2006088955A2 (en) 2005-02-14 2006-02-14 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells

Publications (2)

Publication Number Publication Date
JP2008530137A JP2008530137A (ja) 2008-08-07
JP2008530137A5 true JP2008530137A5 (enExample) 2009-04-02

Family

ID=36685803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007555370A Expired - Fee Related JP4927762B2 (ja) 2005-02-14 2006-02-14 Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
JP2007555369A Pending JP2008530137A (ja) 2005-02-14 2006-02-14 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007555370A Expired - Fee Related JP4927762B2 (ja) 2005-02-14 2006-02-14 Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法

Country Status (8)

Country Link
US (11) US20060188500A1 (enExample)
EP (2) EP1856150A2 (enExample)
JP (2) JP4927762B2 (enExample)
AU (2) AU2006214326B2 (enExample)
CA (2) CA2595877A1 (enExample)
IL (3) IL184734A (enExample)
MX (2) MX2007009471A (enExample)
WO (2) WO2006088956A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135953B1 (en) 1999-06-02 2014-04-23 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, Nr. 10
ES2254224T3 (es) 1999-09-27 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Nueva proteina del receptor de hematopoyetina, nr12.
ES2377188T3 (es) * 2002-01-18 2012-03-23 Zymogenetics, Inc. Nuevo ligando de citocina ZCYTOR17
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2006081573A2 (en) * 2005-01-28 2006-08-03 Zymogenetics, Inc. Homogeneous preparations of il-31
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
WO2006088855A1 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
CN103044550A (zh) * 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
WO2009072598A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 掻痒症治療剤
KR101603109B1 (ko) * 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
US10060273B2 (en) 2015-04-15 2018-08-28 United Technologies Corporation System and method for manufacture of abrasive coating
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2019178601A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Peptide vaccines against interleukin-31
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
CA3096582A1 (en) * 2018-04-25 2019-12-05 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmr.beta. antibodies
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
RU2707181C1 (ru) * 2019-08-15 2019-11-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови
JP6845973B1 (ja) 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
KR102392954B1 (ko) * 2020-02-11 2022-05-02 연세대학교 산학협력단 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
JPWO2003024484A1 (ja) 2001-09-14 2004-12-24 小野薬品工業株式会社 掻痒症治療剤
ES2382800T3 (es) * 2002-01-18 2012-06-13 Zymogenetics, Inc. Multímeros Zcytor17 receptores de citocinas
ES2377188T3 (es) * 2002-01-18 2012-03-23 Zymogenetics, Inc. Nuevo ligando de citocina ZCYTOR17
JPWO2003070252A1 (ja) 2002-02-22 2005-06-09 大正製薬株式会社 止痒剤
JP2004219390A (ja) * 2002-02-22 2004-08-05 Taisho Pharmaceut Co Ltd アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法
JP2004107209A (ja) * 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
JP4503942B2 (ja) * 2003-06-11 2010-07-14 大正製薬株式会社 止痒剤
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
WO2006081573A2 (en) 2005-01-28 2006-08-03 Zymogenetics, Inc. Homogeneous preparations of il-31
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
WO2006088855A1 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
BRPI0611069A2 (pt) * 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5018481B2 (ja) * 2005-09-28 2012-09-05 コニカミノルタアドバンストレイヤー株式会社 射出成形装置
AU2007249713A1 (en) * 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
KR101603109B1 (ko) * 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자

Similar Documents

Publication Publication Date Title
Calcinotto et al. Cellular senescence: aging, cancer, and injury
US11446398B2 (en) Regulated biocircuit systems
JP2008530138A5 (enExample)
JP2020022469A (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
AU2019339469A1 (en) Novel LILRB4 antibodies and uses thereof
KR20200106053A (ko) Atr 억제제를 사용한 암 치료 방법
RU2013153592A (ru) Анти-mif антитела
US11059906B2 (en) Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
KR20220042056A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-siglec-9 조성물 및 방법, 그리고 이의 용도
AU2005265067B2 (en) Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
KR20220042055A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
JP2017506505A5 (enExample)
Diao et al. Telomeric epigenetic response mediated by Gadd45a regulates stem cell aging and lifespan
Kim et al. Hedgehog signaling is associated with liver response to fractionated irradiation in mice
Wang et al. Hepatocyte-specific CC motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
Dou et al. Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR‐Mediated JAK/STAT Signaling and Immune Modulation
CN102641501B (zh) Nalp3-asc炎症复合体及其激活抑制剂在制备朊病毒病药物中的应用
TWI672319B (zh) 用於確認、預測以及治療癌症的方法
Mahmoud et al. Aptabinding of tumor necrosis factor‐α (TNFα) inhibits its proinflammatory effects and alleviates islet inflammation
Zhang et al. Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis
HK1208819A1 (en) Anti-ccl2 antibodies for treatment of scleroderma
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
Li et al. The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis